This article first appeared on GuruFocus .
-
Revenue:$30,000 for Q2 2026, compared to $17,000 in Q2 2025.
-
Operating Expenses:$10 million for the quarter, up slightly from $9.3 million in the prior year period.
-
R&D Expenses:$3.5 million, compared to $3.3 million in 2025, reflecting restructuring-related costs.
-
SG&A Expenses:$6.5 million, versus $6.0 million in the prior year, reflecting investments in targeted commercial activities and marketing programs.
-
Net Loss:$9.1 million for the quarter, compared to a net loss of $8.0 million in Q2 2025.
-
Cash Position:$80.3 million in cash equivalents and available-for-sale securities as of June 30, 2026, expected to fund operations through 2029.
Release Date: August 12, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Sera Prognostics Inc ( NASDAQ:SERA ) achieved a major policy milestone with Illinois Medicaid coverage legislation, providing access to its preterm birth test for tens of thousands of pregnancies annually.
-
The company exceeded its goal for payer engagement, now in discussions with more than 20 payers across over 20 states, driven by referrals and growing market awareness.
-
A new subgroup analysis of the PRIME trial published in July showed a 22% reduction in NICU admissions and a 30% reduction in severe neonatal morbidity in first-time mothers.
-
Sera Prognostics Inc ( NASDAQ:SERA ) launched its fourth partnership program with a national payer, expanding the implementation of its test-guided care and remaining on track to establish five to seven commercial programs.
-
The company's cash position of $80.3 million is expected to fund operations through significant adoption and commercial milestones into 2029.
-
Sera Prognostics Inc ( NASDAQ:SERA ) is advancing its European strategy, with a CE marking submission for its LISA-based assay platform expected in the fourth quarter of 2026.
Negative Points
-
Revenue remains minimal at $30,000 for the quarter, reflecting the early stage of commercialization and the lengthy process of converting market access into testing volume.
-
The timeline for meaningful revenue contribution from the Illinois Medicaid legislation is expected to be slow, with penetration rates of only 1-2% projected for the first full year.
-
The company's net loss widened to $9.1 million in Q2 2026, up from $8.0 million in the same period last year.
-
The CE marking submission for Europe has been delayed to the fourth quarter of 2026 due to the need for additional performance testing, pushing back potential European market entry.
-
The process of converting payer discussions into active contracts and reimbursement is lengthy, with policy reviews taking 9-12 months and implementation periods of 6-9 months before utilization scales.
-
Sera Prognostics Inc ( NASDAQ:SERA ) faces a significant execution challenge in Illinois, requiring contracting with five separate managed Medicaid organizations and extensive provider onboarding before volumes can ramp.
Q & A Highlights
Q: What are the specific steps to move from provider notice to active reimbursement for individual claims in Illinois, and which geographies are likely to follow the Illinois mandate? A: Zhenya Lindgardt, President and CEO, outlined a three-step process: first, provider registration and getting in-network with payers, which can take from a couple of months up to a year; second, contracting with all payers present (five plans in Illinois), typically taking six to nine months; and third, provider activation and education, focusing on major institutions with MFM opinion leaders. She noted several other states have prioritized preterm birth as a healthcare focus, but timelines vary by state legislative sessions, and the company will provide transparency as public signals emerge.
Q: Given the steps required for activation in Illinois, when might the impact be felt, and what is the expected penetration ramp for the 50,000 eligible births? A: Zhenya Lindgardt, President and CEO, stated that the first six months post-reimbursement (from July 1st) will focus on contracting and awareness building, so minimal penetration is expected in 2026. Based on benchmarks from other diagnostic tests, she projected 1-2% penetration in year one (2027), 2-4% in year two, and up to 5% in year three, noting the company aims to outperform these benchmarks.
Q: How should we think about the development of the four partnership programs signed, and what would define success? A: Zhenya Lindgardt, President and CEO, explained that program directors (typically Chief Medical Officers) aim to replicate the successful outcomes from clinical trials in real-life patient populations. The latest program with a national payer focuses on quality metrics the payer is accountable for to the state. Programs vary in structure, with some focusing on value-based care and outcomes, while others focus purely on clinical outcomes.
Q: With engagement across 20 payers in over 20 states, what is the path for converting these opportunities into reimbursement? A: Zhenya Lindgardt, President and CEO, segmented the payer engagement into three categories: (1) payers undergoing policy review, which typically takes 9-12 months for national payers and concludes with a definitive decision; (2) payers interested in launching partnership programs in specific geographies, particularly for Medicaid quality metrics; and (3) payers exploring implementation with specific customers or providers to demonstrate real-time results.
Q: What are the updated thoughts on guideline inclusion, and will the upcoming SMFM oral presentation feature new data? A: Zhenya Lindgardt, President and CEO, stated the company is executing on advice from ACOG and SMFM to publish as much data as possible from the PRIME dataset, with a pipeline of additional analyses coming in the next year or two. Regarding the SMFM presentation, she confirmed it will feature the already-published data on first-time mothers, not new data.
Q: What led to the decision to delay the CE marking submission to Q4, and was it related to feedback from the European advisory board? A: Zhenya Lindgardt, President and CEO, clarified the decision was internal, not from the advisory board. The delay is due to additional performance testing on the ELISA-based assay platform, specifically regarding sample stability during transport to the lab for analysis. This is intended to de-risk execution and strengthen the overall regulatory package, with the company remaining on track for submission by year-end.
Q: How has the dialogue with the clinical community changed now that PRIME data is published, and what will the SMFM presence look like? A: Zhenya Lindgardt, President and CEO, noted the dialogue has shifted dramatically from basic clinical utility to deeper conversations about biology, biomarker pathways, and validation of SHBG and IBP-4 biomarkers. The clinical community has moved past "does this test work" to asking what other conditions the test enriches for, signaling a transition from validation to acceptance and implementation.
Q: Can you provide more detail on the financial results for the quarter and the company's cash position? A: Austin Aerts, CFO, reported revenue of $30,000 for Q2 2026, up from $17,000 in Q2 2025. Operating expenses were $10 million, up slightly from $9.3 million, with R&D at $3.5 million and SG&A at $6.5 million. Net loss was $9.1 million, compared to $8.0 million in the prior year. The company ended with $80.3 million in cash, sufficient to fund operations through 2029.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
